Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist
Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)?
Credit available for this activity expires: 11/21/24
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/998529?ecd=bdc_podcast_libsyn_mscpedu
Create your
podcast in
minutes
It is Free